Direct Healthcare Professional Communication: Interaction between sodium stibogluconate (Pentostam®) and amphotericin B deoxycholate

Source: MHRA Area: News GlaxoSmithKline has issued a Direct Healthcare Professional Communication regarding new interaction details for sodium stibogluconate (Pentostam®), which have been added to the product information.   An increased risk of fatal cardiac arrhythmias has been observed when amphotericin B deoxycholate is administered soon after sodium stibogluconate during retreatment of visceral leishmaniasis. Although the mechanism is unknown, it is suggested that sodium stibogluconate increases the susceptibility of the myocardium to damage by amphotericin B deoxycholate.   Sections 4.4 and 4.5 have been updated accordingly.
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news